Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)

Next Previous
Search
Trial Profile

Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-Tianjin-Mycure-Medical-Technology (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Tianjin Mycure Medical Technology

    • Most Recent Events

    • 01 Mar 2022 Results from rom 5 clinical trials (NCT03173417, NCT02546739, NCT03671460, ChiCTR-ONC-17012829, and ChiCTR1800016541) assessing Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia published in the Cancer Immunology Immunotherapy
    • 14 Dec 2021 Results (n=64 ) from NCT03173417, NCT02546739, NCT03312205 and NCT03671460; analysing factors associated with efficacy following CD19 CAR-T therapy among B-ALL patients with TP53 mutation/chromosome 17p deletion, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 08 Dec 2020 Results of an analysis from five clinical trials: NCT03173417, ChiCTR-ONC-17012829, NCT02546739, ChiCTR1800016541 and NCT03671460 presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top